Stock MDP MEDEXUS PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Market Closed - Toronto S.E.
Other stock markets
 03:59:39 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.92 CAD +3.23% Intraday chart for Medexus Pharmaceuticals Inc. +16.36% -22.27%
Mar. 26 Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R) CI
Feb. 09 Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
NE
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY to Treat Hemophilia B in Pediatric Patients
AQ
Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)
CI
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
NE
Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85
MT
Medexus Pharmaceuticals Down 30% After Announces Fiscal Q3 2024 Results
MT
Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results
MT
Transcript : Medexus Pharmaceuticals Inc., Q3 2024 Earnings Call, Feb 08, 2024
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Medexus Announces Fiscal Q3 2024 Results
NE
North American Morning Briefing : Stock Futures Hold Line Ahead of More Earnings, Fedspeak
DJ
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
NE
Medexus Pharmaceuticals - Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
AQ
Medexus Pharmaceuticals Says Health Canada to Review New Drug Submission for Topical Terbinafine
MT
Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections
CI
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
NE
Transcript : Medexus Pharmaceuticals Inc., Q2 2024 Earnings Call, Nov 09, 2023
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
NE
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Medexus Schedules Second Fiscal Quarter 2024 Conference Call
NE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDP Stock
  4. News Medexus Pharmaceuticals Inc.